Evotec Receives Milestone Payment from Boehringer Ingelheim
News Jul 30, 2009
Evotec AG has announced that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim.
The milestone was achieved for the identification and selection of a second compound to be advanced into preclinical development within an existing program. This represents the sixth milestone achieved in this multi-year, multi-target collaboration and is the second compound selected for pre-development in the last twelve months.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “It is great to see the scientific progress that top-class discovery alliance projects can bring. We are jointly progressing several projects with Boehringer Ingelheim at this stage, so we are optimistic to see further product progress soon.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019